Qualcomm, Novartis To Invest In Mobile Health, Aggregate Trial Data
This article was originally published in The Gray Sheet
The companies say they are partnering to invest in start-ups that have potential to change healthcare delivery and are using Qualcomm’s 2net Platform in a clinical trial to aggregate patient data and personalize treatments.
You may also be interested in...
Recent activities by three smartphone giants point to a potential future where the phone itself more frequently serves as a monitoring or diagnosing device, in place of external sensors. If the trend rolls on, it could have important implications for the mobile health sector.
Digital Health Briefs: Post-Surgery Remote Monitoring; NHS England Technology Funding; Qualcomm Product
Study finds remote monitoring can assess patient mobility and correlates with length of stay. NHS England boosts technology fund by 250 million pounds. Qualcomm introduces 2net Mobile. More digital news.
Amneal is close to a filed pipeline of three biosimilar products in the US, while furthering ambitions in the complex generics and 505(b)(2) space, management told the virtual J.P. Morgan Healthcare Conference.